Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 3
1972 3
1973 2
1975 2
1976 1
1978 4
1980 1
1981 5
1982 2
1983 1
1984 3
1985 3
1986 4
1987 11
1988 4
1989 2
1990 2
1991 3
1992 2
1993 2
1994 1
1995 4
1996 2
1997 2
1998 1
1999 1
2000 3
2001 3
2002 2
2003 2
2004 4
2005 3
2006 3
2007 2
2008 2
2009 4
2010 4
2011 1
2012 5
2013 4
2014 9
2015 7
2016 3
2017 2
2018 4
2019 2
2020 1
2021 3
2022 1
2023 5
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effect of bromhexine in hospitalized patients with COVID-19.
Tolouian R, Mulla ZD, Jamaati H, Babamahmoodi A, Marjani M, Eskandari R, Dastan F. Tolouian R, et al. J Investig Med. 2023 Oct;71(7):691-699. doi: 10.1136/jim-2020-001747. J Investig Med. 2023. PMID: 33722999 Clinical Trial.
BACKGROUND: Bromhexine is a potent inhibitor of transmembrane serine protease 2 and appears to have an antiviral effect in controlling influenza and parainfluenza infection; however, its efficacy in COVID-19 is controversial. ...There were also no differences observed in t …
BACKGROUND: Bromhexine is a potent inhibitor of transmembrane serine protease 2 and appears to have an antiviral effect in controllin …
Bromhexine in chronic bronchitis.
Christensen F, Kjer J, Ryskjaer S, Arseth-Hansen P. Christensen F, et al. Br Med J. 1970 Oct 10;4(5727):117. doi: 10.1136/bmj.4.5727.117-a. Br Med J. 1970. PMID: 4919405 Free PMC article. Clinical Trial. No abstract available.
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study.
Li T, Sun L, Zhang W, Zheng C, Jiang C, Chen M, Chen D, Dai Z, Bao S, Shen X. Li T, et al. Clin Transl Sci. 2020 Nov;13(6):1096-1102. doi: 10.1111/cts.12881. Epub 2020 Oct 10. Clin Transl Sci. 2020. PMID: 32881359 Free PMC article. Clinical Trial.
This open-label randomized controlled pilot study aimed to test the study feasibility of bromhexine hydrochloride (BRH) tablets for the treatment of mild or moderate coronavirus disease 2019 (COVID-19) and to explore its clinical efficacy and safety. ...
This open-label randomized controlled pilot study aimed to test the study feasibility of bromhexine hydrochloride (BRH) tablets for t …
Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Ohnishi H, Tanimoto T, Inaba R, Eitoku M. Ohnishi H, et al. Respir Investig. 2024 Nov;62(6):1168-1175. doi: 10.1016/j.resinv.2024.10.004. Epub 2024 Oct 15. Respir Investig. 2024. PMID: 39413571
METHODS: Reports from randomized controlled trials to evaluate the efficacy and safety of mucolytics, including ambroxol, bromhexine, carbocisteine, erdosteine, fudosteine, l-methylcysteine, and N-acetylcysteine used in patients with stable COPD were searched for in PubMed …
METHODS: Reports from randomized controlled trials to evaluate the efficacy and safety of mucolytics, including ambroxol, bromhexine, …
Mucolytics for bronchiectasis.
Wilkinson M, Sugumar K, Milan SJ, Hart A, Crockett A, Crossingham I. Wilkinson M, et al. Cochrane Database Syst Rev. 2014 May 2;2014(5):CD001289. doi: 10.1002/14651858.CD001289.pub2. Cochrane Database Syst Rev. 2014. PMID: 24789119 Free PMC article. Review.
A reduction in sputum production was noted with bromhexine (MD -21.5%, 95% CI -38.9 to -4.1 at day 16); again the quality of the evidence was rated as low. ...As the number of agents available on the market, such as RhDNase, acetylcysteine and bromhexine, is increas …
A reduction in sputum production was noted with bromhexine (MD -21.5%, 95% CI -38.9 to -4.1 at day 16); again the quality of the evid …
Bromhexine in the treatment of otitis media with effusion.
Stewart IA, Guy AM, Allison RS, Thomson NJ. Stewart IA, et al. Clin Otolaryngol Allied Sci. 1985 Jun;10(3):145-9. doi: 10.1111/j.1365-2273.1985.tb01183.x. Clin Otolaryngol Allied Sci. 1985. PMID: 3896583 Clinical Trial.
There were 198 ears in the placebo group and 182 ears in the bromhexine group. The resolution rate in the placebo treated group was 19% and in the bromhexine treated group 16%. Bromhexine does not appear to be a useful drug for the treatment of OME in childre …
There were 198 ears in the placebo group and 182 ears in the bromhexine group. The resolution rate in the placebo treated group was 1 …
Sjorgren's syndrome treated with bromhexine: a randomised clinical study.
Frost-Larsen K, Isager H, Manthorpe R. Frost-Larsen K, et al. Br Med J. 1978 Jun 17;1(6127):1579-81. doi: 10.1136/bmj.1.6127.1579. Br Med J. 1978. PMID: 350346 Free PMC article. Clinical Trial.
In the first trial bromhexine 24 mg/day was given by mouth; in the second the dose was increased to 48 mg/day. ...It had no effect on salivary gland function. Bromhexine is therefore valuable in the treatment of Sjogren's syndrome....
In the first trial bromhexine 24 mg/day was given by mouth; in the second the dose was increased to 48 mg/day. ...It had no effect on …
Bioavailability of bromhexine tablets and preliminary pharmacokinetics in humans.
Bechgaard E, Nielsen A. Bechgaard E, et al. Biopharm Drug Dispos. 1982 Oct-Dec;3(4):337-44. doi: 10.1002/bdd.2510030407. Biopharm Drug Dispos. 1982. PMID: 6897618 Clinical Trial.
The absorption of bromhexine from Bromhexin tablets 8 mg, DAK has been compared with that from Bisolvon tablets 8 mg, Boehringer Ingelheim, in a two-way complete crossover study. Four tablets of each of the two bromhexine products, corresponding to a single d …
The absorption of bromhexine from Bromhexin tablets 8 mg, DAK has been compared with that from Bisolvon tablets 8 mg, Boehring …
Evaluation of the efficacy of N-acetylcysteine and bromhexine compared with standard care in preventing hospitalization of outpatients with COVID-19: a double blind randomized clinical trial.
Eslami Ghayour A, Nazari S, Keramat F, Shahbazi F, Eslami-Ghayour A. Eslami Ghayour A, et al. Rev Clin Esp (Barc). 2024 Feb;224(2):86-95. doi: 10.1016/j.rceng.2023.12.011. Epub 2024 Jan 11. Rev Clin Esp (Barc). 2024. PMID: 38215974 Clinical Trial.
RESULTS: The study found that both N-acetylcysteine and Bromhexine can effectively reduce hospitalization rates and mortality and shorten the duration of hospitalization. ...CONCLUSION: In conclusion, the results of this study indicate that NAC and bromhexine may be …
RESULTS: The study found that both N-acetylcysteine and Bromhexine can effectively reduce hospitalization rates and mortality and sho …
New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial).
Granados-Montiel J, Hazan-Lasri E, Franco-Cendejas R, Chávez-Heres T, Silva-Bermudez P, Aguilar-Gaytán R, Manzano-León N, Méndez-Maldonado K, Alvarez-Arce A, Martínez-Portilla RJ. Granados-Montiel J, et al. BMJ Open. 2021 Aug 3;11(8):e045190. doi: 10.1136/bmjopen-2020-045190. BMJ Open. 2021. PMID: 34344672 Free PMC article. Clinical Trial.
We propose studying prophylactic treatment with hydroxychloroquine (HCQ) and bromhexine (BHH), which have been shown to be effective in preventing SARS-CoV-2 infection progression when administered in early stages. ...
We propose studying prophylactic treatment with hydroxychloroquine (HCQ) and bromhexine (BHH), which have been shown to be effective …
154 results